At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
IOBT IO Biotech, Inc.
Market Closed 10-04 16:00:00 EDT
1.15
+0.14
+13.86%
盘后1.13
-0.02-1.63%
19:14 EDT
High1.19Low1.02Vol372.08K
Open1.02D1 Closing1.01Amplitude16.95%
Mkt Cap75.76MTradable Cap32.02MTotal Shares65.88M
T/O419.50KT/O Rate1.34%Tradable Shares27.84M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--
IO Biotech Announces Two Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting
GlobeNewswire  ·  10-04 21:00
IO Biotech Announces Two Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting
Buy Rating on IO Biotech’s IO102/103 Fueled by Positive KOL Feedback and Phase 2 Data
TIPRANKS  ·  10-04 20:15
Buy Rating on IO Biotech’s IO102/103 Fueled by Positive KOL Feedback and Phase 2 Data
Wall Street Analysts Are Bullish on Top Healthcare Picks
TIPRANKS  ·  09-18
Wall Street Analysts Are Bullish on Top Healthcare Picks
IO Biotech Is Maintained at Overweight by Morgan Stanley
Dow Jones  ·  09-16
IO Biotech Is Maintained at Overweight by Morgan Stanley
IO Biotech Price Target Maintained With a $12.00/Share by HC Wainwright & Co.
Dow Jones  ·  09-16
IO Biotech Price Target Maintained With a $12.00/Share by HC Wainwright & Co.
Piper Sandler Sticks to Its Buy Rating for IO Biotech (IOBT)
TIPRANKS  ·  09-16
Piper Sandler Sticks to Its Buy Rating for IO Biotech (IOBT)
Buy Rating for IO Biotech Backed by Promising ESMO Data and Superior Efficacy of IO102-IO103 Combination Therapy
TIPRANKS  ·  09-16
Buy Rating for IO Biotech Backed by Promising ESMO Data and Superior Efficacy of IO102-IO103 Combination Therapy
IO Biotech Announces Positive Results From Phase 2 Trial of IO102-IO103 in the First-Line Treatment of Advanced Head and Neck Cancer
THOMSON REUTERS  ·  09-14
IO Biotech Announces Positive Results From Phase 2 Trial of IO102-IO103 in the First-Line Treatment of Advanced Head and Neck Cancer
IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of Advanced Head and Neck Cancer
GlobeNewswire  ·  09-14
IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of Advanced Head and Neck Cancer
IO Biotech Is Maintained at Overweight by Piper Sandler
Dow Jones  ·  09-03
IO Biotech Is Maintained at Overweight by Piper Sandler
IO Biotech Inc : Jefferies Cuts Target Price to $8 From $10
THOMSON REUTERS  ·  09-03
IO Biotech Inc : Jefferies Cuts Target Price to $8 From $10
IO Biotech Price Target Maintained With a $12.00/Share by HC Wainwright & Co.
Dow Jones  ·  09-03
IO Biotech Price Target Maintained With a $12.00/Share by HC Wainwright & Co.
Optimistic Outlook on IO Biotech’s PFS Improvements Despite ORR Setback
TIPRANKS  ·  09-03
Optimistic Outlook on IO Biotech’s PFS Improvements Despite ORR Setback
IO Biotech Inc : Morgan Stanley Cuts Target Price to $4 From $7
THOMSON REUTERS  ·  09-03
IO Biotech Inc : Morgan Stanley Cuts Target Price to $4 From $7
Buy Rating Affirmed for IO Biotech Amid Positive Phase 3 Trial Progress and Historical Data
TIPRANKS  ·  09-03
Buy Rating Affirmed for IO Biotech Amid Positive Phase 3 Trial Progress and Historical Data
IO Biotech Gets Data Monitoring Committee Recommendation to Continue Phase 3 Melanoma Study
MT Newswires Live  ·  08-31
IO Biotech Gets Data Monitoring Committee Recommendation to Continue Phase 3 Melanoma Study
IO Biotech’s Promising Phase 3 Cancer Vaccine Trial Advances
TIPRANKS  ·  08-31
IO Biotech’s Promising Phase 3 Cancer Vaccine Trial Advances
IO Biotech Inc - Primary Endpoint of Progression Free Survival Projected to Be Reached in First Half of 2025
THOMSON REUTERS  ·  08-31
IO Biotech Inc - Primary Endpoint of Progression Free Survival Projected to Be Reached in First Half of 2025
IO Biotech Inc - Idmc Recommends Trial Continue Without Modifications
THOMSON REUTERS  ·  08-31
IO Biotech Inc - Idmc Recommends Trial Continue Without Modifications
IO Biotech Inc - No New Safety Signals Observed at Interim Analysis
THOMSON REUTERS  ·  08-31
IO Biotech Inc - No New Safety Signals Observed at Interim Analysis

Introduction

Company Name.
IO Biotech, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.
Issue price:
--